Logo image
Back
Genomic characterisation of linezolid-resistant Enterococcus faecalis from Western Australia 2016–2021
Journal article   Open access   Peer reviewed

Genomic characterisation of linezolid-resistant Enterococcus faecalis from Western Australia 2016–2021

Shakeel Mowlaboccus, Denise A. Daley and Geoffrey W. Coombs
Pathology, Vol.55(3), pp.397-399
2023
DOI: https://doi.org/10.1016/j.pathol.2022.06.002
PMID: 36085088
url
https://doi.org/10.1016/j.pathol.2022.06.002View
Published (Version of Record) Open

Abstract

To the Editor, Linezolid (LNZ) is an oxazolidinone antibiotic and a drug of last resort used to treat infections caused by Gram-positive pathogens that are resistant to multiple classes of antibiotics. In Australia, LNZ was introduced in 2002 and is currently reserved to treat suspected or proven infections caused by methicillin-resistant staphylococci or vancomycin-resistant enterococci. Despite restricted use, LNZ resistance has emerged worldwide, threatening the effective treatment of multidrug-resistant bacterial infections.1 In Australia, LNZ-resistant enterococci (LRE) are monitored and reported by each state and territory to the National Alert System for Critical Antimicrobial Resistances (CARAlert), as part of the AURA (Antimicrobial Use and Resistance in Australia) surveillance system...

Details

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

Source: InCites

Metrics

23 Record Views
4 Times Cited - Web of Science

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types
Domestic collaboration
Citation topics
1 Clinical & Life Sciences
1.23 Antibiotics & Antimicrobials
1.23.173 MRSA and VRE
Web Of Science research areas
Pathology
ESI research areas
Clinical Medicine
Logo image